You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 8, 2025

CLINICAL TRIALS PROFILE FOR YERVOY


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for YERVOY

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed Medarex Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed U.S. Army Medical Research Acquisition Activity Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed United States Department of Defense Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed Mayo Clinic Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for YERVOY

Condition Name

Condition Name for YERVOY
Intervention Trials
Melanoma 42
Metastatic Melanoma 26
Renal Cell Carcinoma 14
Non-small Cell Lung Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for YERVOY
Intervention Trials
Melanoma 88
Carcinoma 54
Carcinoma, Renal Cell 33
Lung Neoplasms 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for YERVOY

Trials by Country

Trials by Country for YERVOY
Location Trials
Japan 189
China 125
Australia 123
Canada 92
Spain 76
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for YERVOY
Location Trials
Texas 106
California 93
Pennsylvania 75
Massachusetts 75
New York 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for YERVOY

Clinical Trial Phase

Clinical Trial Phase for YERVOY
Clinical Trial Phase Trials
Phase 4 3
Phase 3 20
Phase 2/Phase 3 7
[disabled in preview] 176
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for YERVOY
Clinical Trial Phase Trials
Recruiting 107
Active, not recruiting 69
Completed 44
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for YERVOY

Sponsor Name

Sponsor Name for YERVOY
Sponsor Trials
Bristol-Myers Squibb 133
National Cancer Institute (NCI) 53
M.D. Anderson Cancer Center 35
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for YERVOY
Sponsor Trials
Other 265
Industry 237
NIH 55
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

YERVOY: A Comprehensive Update on Clinical Trials, Market Analysis, and Projections

Last updated: January 4, 2025

Introduction to YERVOY

YERVOY, also known as ipilimumab, is a monoclonal antibody that targets the CTLA-4 receptor, playing a crucial role in cancer immunotherapy. Developed by Bristol Myers Squibb, YERVOY has been a game-changer in the treatment of various cancers, particularly melanoma and other advanced malignancies.

Clinical Trials and Efficacy

Long-Term Survival Benefits in Melanoma

Recent data from the CheckMate 067 trial has highlighted the long-term efficacy of YERVOY in combination with Opdivo (nivolumab) for patients with advanced melanoma. After a 10-year follow-up, the study revealed that 43% of patients who received the combination therapy were alive, significantly improving the median overall survival to 71.9 months. This is the longest reported median overall survival in a Phase III advanced melanoma trial to date[1].

Improved Survival in Hepatocellular Carcinoma

The CheckMate -9DW trial demonstrated that the combination of Opdivo and YERVOY significantly improved survival benefits compared to lenvatinib or sorafenib in patients with advanced hepatocellular carcinoma (HCC). The objective response rate for the combination was more than double that of the control arm, with a median duration of response of 30 months[4].

Market Analysis

Current Market Size and Growth

The YERVOY market was valued at USD 7.5 billion in 2023 and is projected to reach USD 15 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 8% from 2024 to 2031. This growth is driven by the expanding clinical uses and new indications for YERVOY, particularly in treating melanoma and non-small cell lung cancer[3].

Regional Analysis

The market for YERVOY is segmented geographically into North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa. The increasing global prevalence of cancer and the need for sophisticated treatment solutions are key drivers of market growth across these regions. Strategic alliances and partnerships among pharmaceutical companies also support the market position of YERVOY[3].

Market Projections

Expanding Clinical Uses

The market for YERVOY is expected to grow significantly due to its proven effectiveness in cancer immunotherapy. The drug's use is expanding beyond melanoma to include other cancers such as non-small cell lung cancer. Ongoing clinical trials and the approval of new indications are further propelling the market growth[3].

Impact of Immunotherapy

Immunotherapies, including YERVOY, are becoming increasingly integral to cancer treatment algorithms. In the non-small cell lung cancer (NSCLC) market, for example, immunotherapies are projected to account for 65% of total sales by 2025, with YERVOY and other checkpoint inhibitors like Opdivo and Keytruda leading the charge[5].

Key Factors Driving Market Growth

Rising Global Prevalence of Cancer

The soaring incidence of cancer worldwide is a major driver of the YERVOY market. As cancer cases increase, the demand for effective and innovative treatments like YERVOY rises, contributing to market growth[3].

Continued R&D Initiatives

Pharmaceutical companies are investing heavily in research and development, which is driving the advancement of YERVOY and other immunotherapies. These initiatives are extending the clinical uses of YERVOY and enhancing its market position[3].

Strategic Alliances and Partnerships

Collaborations between pharmaceutical companies are crucial for the development and commercialization of YERVOY. These alliances support the market expansion by facilitating access to new technologies, markets, and patient populations[3].

Challenges and Opportunities

Safety Profile and Adverse Events

While the combination of Opdivo and YERVOY has shown significant efficacy, it also comes with a notable safety profile. Treatment-related adverse events (TRAEs) are common, with 84% of patients experiencing TRAEs of any grade. However, these adverse events are generally manageable with established protocols[4].

Market Competition

The immunotherapy market is highly competitive, with other checkpoint inhibitors like Keytruda and Tecentriq also vying for market share. However, YERVOY's established position and ongoing clinical successes help it maintain a strong market presence[5].

Conclusion

YERVOY has revolutionized the treatment landscape for advanced melanoma and other cancers, offering durable long-term survival benefits. With a growing market valued at USD 7.5 billion in 2023 and projected to reach USD 15 billion by 2031, YERVOY continues to be a cornerstone in cancer immunotherapy.

Key Takeaways

  • Long-Term Efficacy: YERVOY in combination with Opdivo has demonstrated a 43% survival rate at 10 years for patients with advanced melanoma.
  • Expanding Indications: YERVOY is being explored for use in various cancers, including hepatocellular carcinoma.
  • Market Growth: The YERVOY market is expected to grow at a CAGR of 8% from 2024 to 2031.
  • Global Prevalence: The rising incidence of cancer globally is driving the demand for YERVOY.
  • R&D Initiatives: Continued research and development are extending the clinical uses of YERVOY.

FAQs

Q: What is YERVOY used for?

YERVOY (ipilimumab) is used primarily for the treatment of unresectable or metastatic melanoma. It is also being explored for use in other cancers such as hepatocellular carcinoma.

Q: How effective is the combination of Opdivo and YERVOY in melanoma treatment?

The combination of Opdivo and YERVOY has shown a significant improvement in overall survival for patients with advanced melanoma, with a 43% survival rate at 10 years.

Q: What are the key drivers of the YERVOY market growth?

The key drivers include the expanding clinical uses, rising global prevalence of cancer, continued R&D initiatives, and strategic alliances among pharmaceutical companies.

Q: What are the common adverse events associated with YERVOY?

Treatment-related adverse events (TRAEs) are common, with 84% of patients experiencing TRAEs of any grade. However, these adverse events are generally manageable.

Q: How does YERVOY compare to other immunotherapies in the market?

YERVOY competes with other checkpoint inhibitors like Keytruda and Tecentriq but maintains a strong market presence due to its established efficacy and ongoing clinical successes.

Sources

  1. Biospace: BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years.
  2. Biospace: Melanoma Market to Reach USD 8.9 Billion by 2034.
  3. Market Research Intellect: Yervoy Market Size, Share, Industry Report 2024-31.
  4. Bristol Myers Squibb: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival.
  5. GlobalData: NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.